News headlines about iCAD (NASDAQ:ICAD) have trended positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. iCAD earned a news impact score of 0.28 on Accern’s scale. Accern also assigned media headlines about the technology company an impact score of 45.5664817636144 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Separately, ValuEngine lowered iCAD from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 20th.
iCAD (NASDAQ:ICAD) traded down $0.23 during trading hours on Tuesday, hitting $3.65. The stock had a trading volume of 21,100 shares, compared to its average volume of 54,160. The firm has a market capitalization of $60.83, a price-to-earnings ratio of -4.45 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.67 and a current ratio of 1.95. iCAD has a 1-year low of $3.13 and a 1-year high of $6.07.
WARNING: “Favorable Media Coverage Somewhat Unlikely to Affect iCAD (ICAD) Stock Price” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.com-unik.info/2018/01/09/favorable-media-coverage-somewhat-unlikely-to-affect-icad-icad-stock-price.html.
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.